Table 2. Univariable and multivariable analyses of BMI categories and PFS.
| Factors | Number of women with recurrence within 3 years | Crude | Adjusted | |
|---|---|---|---|---|
| p-value | HR (95% CI) | p-value | ||
| BMI category | ||||
| Obese (≥30 kg/m2) | 19/23 (82.6%) | 0.044 | 0.69 (0.40–1.16) | 0.160 |
| Non-obese (<30 kg/m2) | 64/103 (62.1%) | 1.00 (reference) | ||
| Age | ||||
| <52 years | 34/62 (54.8%) | 0.005 | 1.88 (1.21–2.92) | 0.005 |
| ≥52 years | 49/64 (76.6%) | 1.00 (reference) | ||
| Parity | ||||
| Nulliparity | 25/47 (53.2%) | 0.015 | 1.50 (0.91–2.47) | 0.112 |
| Multiparity | 58/79 (73.4%) | 1.00 (reference) | ||
| Menstrual status | ||||
| Pre-menopause | 41/66 (62.1%) | 0.523 | NA | NA |
| Post-menopause | 42/60 (70.0%) | |||
| Serum CA-125 levels | ||||
| ≥470 U/mL | 39/61 (63.9%) | 0.588 | NA | NA |
| <470 U/mL | 44/65 (67.7%) | |||
| Medical comorbidity | ||||
| Yes | 23/30 (76.7%) | 0.262 | NA | NA |
| No | 60/96 (62.5%) | |||
| Presence of ascites | ||||
| Yes | 48/71 (67.6%) | 0.263 | NA | NA |
| No | 35/55 (63.6%) | |||
| FIGO stage | ||||
| Stage 3 | 54/85 (63.5%) | 0.313 | NA | NA |
| Stage 4 | 29/41 (70.7%) | |||
| Surgical debulking status | ||||
| Optimal | 28/38 (73.7%) | 0.175 | NA | NA |
| Suboptimal | 55/88 (62.5%) | |||
| Upfront surgery | ||||
| PDS | 46/67 (68.7%) | 0.396 | NA | NA |
| IDS | 37/59 (62.7%) | |||
| Histological subtype | ||||
| Type I | 27/46 (58.7%) | 0.305 | NA | NA |
| Type II | 56/80 (70.0%) | |||
BMI (body mass index), CA (cancer antigen), CI (confidence interval), FIGO (International Federation of Gynaecology and Obstetrics), HR (hazard ratio), NA (not applicable), PDS (primary debulking surgery); Type I includes low-grade serous carcinomas and other similar cancers; Type II includes high-grade serous carcinomas.